Latest Diovan news
FDA Finds Another Carcinogen in Certain Valsartan Heart Meds
posted September 14th
by modernClinician Editorial Team
by modernClinician Editorial Team
The U.S. Food and Drug Administration warns that it has found a second impurity in three lots of Torrent Pharmaceuticals' valsartan drug products.
No Apparent Short-Term Cancer Risk From Recalled Valsartan
posted September 13th
by modernClinician Editorial Team
by modernClinician Editorial Team
Users of valsartan contaminated with N-nitrosodimethylamine seem not to have increased cancer risk, according to a study published online Sept. 12 in The BMJ.
FDA Recalls Drugs Containing Active Ingredient Valsartan
posted July 19th
by modernClinician Editorial Team
by modernClinician Editorial Team
Several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure, are being recalled due to an impurity, N-nitrosodimethylamine, that has been found in the recalled products, according to the U.S. Food and Drug Administration.
Inclined Sleeper-Associated Sudden Unexpected Infant Deaths Continued After Recall 
FDA Now Providing Daily Updates on Adverse Events 
FDA Suspends U.S. License of Chikungunya Vaccine 
FDA Urges Restrictions, Education on Illegal 7-OH Opioid Products Related Articles
Withdrawal From Medetomidine Increasingly Seen in ICUs .jpg)
Considerable Gaps Reported in Care for Youth With Opioid Use Disorder 
Study Looks at Patient Experiences With Sedative Contaminating Fentanyl 
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder Monthly Specialist Briefings
Stay Connected
